Start-Ups & SMEs
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Finance Watch: Mega-Rounds Around The World As VCs Spread The Wealth
Private Company Edition: After US-based Alumis and Sionna raised $259m and $182m, respectively, in series C rounds, Tubulis in Munich, Germany brought in €128m ($138.8m) in series B2 cash, while Rakuten – with offices in the US, Europe and Asia – closed a $119m series E round.
Andera Reflects On Revitalized Biotech Scene
After AstraZeneca’s acquisition of Amolyt made the Paris-based investment group a tidy profit, Andera spoke to Scrip about the rejuvenated investment market in Europe.
Mission Therapeutics Raises Funds For Parkinson’s Disease Protein Modulator
New funding for the UK biotech reflects growing interest in finding ways to remove dysfunctional proteins from the body.
Hopes For A ‘New Era’ In UK Biotech Financing With Pension-Backed Fund
Backed by the UK government and the Phoenix Group, the initial £200m fund is aimed at convincing pension funds to invest in the higher-risk, higher-reward life sciences sector.
Merck KGaA Is Latest Partner For C4 Therapeutics’ Protein Degradation
New deal shows growing big pharma interest in protein degradation, with C4 expecting multiple in-house updates this year.
Finance Watch: FogPharma’s Platform Against Unreachable Targets Attracts $145m Series E
Private Company Edition: FogPharma raised $145m for its clinical-stage drug and earlier programs after bringing on former Johnson & Johnson R&D head Mathai Mammen as CEO last year. Also, BlossomHill closed a $100m series B round and Kenai emerged with $82m in series A cash.
Finance Watch: Frontier Raises $80m For Differentiated KRAS G12C Program
Private Company Edition: With its lead program in the clinic, Frontier’s $80m series C round will fund trials for additional programs. Also, ORI raises $260m for second fund, Earlybird closed a €173m ($187.1m) fund, Areteia’s series A grew to $425m and Sudo’s series B increased to $147m.
Ambitious AAX Wants To Be Key Player In Next-Generation Antibodies
Emerging Company Profile: The Swedish biotech’s CEO Maria Lisa Knudsen believes that the firm’s two technologies make it an attractive prospective partner for big pharma.
IsomAb Nabs Decent Seed Funding Despite Tricky Funding Climate
The University of Nottingham spin-out has raised £7.5m for a candidate that could halt the progression of peripheral arterial disease in diabetics.
Aurinia Make Cuts After Fruitless Search For Buyer
The company will now focus on maximizing uptake of its lupus nephritis treatment Lupkynis.
Latigo Raises $135m To Channel Vertex
The start-up is aiming to develop a NaV1.8 inhibitor for pain, but previous efforts here have met with more failure than success.
BioAge Puts VC Muscle Behind Phase II Azelaprag Trials In Obesity
The company completed a $170m series D round and plans to start trials combining the drug with GLP-1 agonists like Eli Lilly’s Zepbound in mid-2024.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Article
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.